Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
University College, London
BeOne Medicines
M.D. Anderson Cancer Center
University of Chicago
Dana-Farber Cancer Institute
Eli Lilly and Company
Alliance for Clinical Trials in Oncology
University of Wisconsin, Madison
Massachusetts General Hospital
National Institutes of Health Clinical Center (CC)
Sanofi
National Cancer Institute (NCI)
University of Washington
City of Hope Medical Center
Institut Bergonié
Incyte Corporation
Insel Gruppe AG, University Hospital Bern
University of Washington
International Extranodal Lymphoma Study Group (IELSG)
National Institutes of Health Clinical Center (CC)
SWOG Cancer Research Network
City of Hope Medical Center
University of Miami
National Cancer Institute (NCI)
Juno Therapeutics, a Subsidiary of Celgene
Antengene Corporation
Janssen Research & Development, LLC
ADC Therapeutics S.A.
M.D. Anderson Cancer Center
Celgene
BeiGene
BeiGene
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Novartis
Debiopharm International SA
CTI BioPharma
Xencor, Inc.
Novartis
IRCCS San Raffaele
City of Hope Medical Center
City of Hope Medical Center
Juno Therapeutics, a Subsidiary of Celgene
National Institutes of Health Clinical Center (CC)
University of Nebraska
MorphoSys AG
Hoffmann-La Roche
University of Nebraska
University of Nebraska
University of Nebraska